KAIROS PHARMA LTD (KAPA) Stock Price, Quote, News and Overview
NYSEARCA:KAPA - NYSE Arca - US48301N1046 - Common Stock - Currency: USD
KAPA Quote, Performance and Key Statistics
1.33
+0.01 (+0.76%)
The current stock price of KAPA is 1.33 USD. In the past month the price decreased by -18.4%.
KAPA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.85 | 354.98B | ||
| AMGN | AMGEN INC | 15.03 | 159.99B | ||
| GILD | GILEAD SCIENCES INC | 23.87 | 137.10B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1656.31 | 123.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.25 | 76.09B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.34B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.37B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.06B | ||
| NTRA | NATERA INC | N/A | 22.20B | ||
| BIIB | BIOGEN INC | 8.32 | 19.98B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.01B |
Related stock screener links
About KAPA
Company Profile
Kairos Pharma Ltd is a US-based company operating in Biotechnology industry. The company is headquartered in Los Angeles, California. The company went IPO on 2024-09-16. Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its products consist of five pre-clinical or clinical-trial stage drug candidates developed by it and designed to target immune response, and two therapeutic agents developed by its Enviro Therapeutics, Inc. (Enviro) subsidiary and designed to increase anti-tumor response in conjunction with cancer therapies by addressing resistance to these agents. Its product portfolio includes a variety of technologies licensed by its Enviro subsidiary and consists of compositions and methods for treating diseases and conditions by targeting CD105 and depleting mitochondrial DNA from the circulation. Its products include KROS 101, 102, 201, 301, 401, ENV 105 and 205.
Company Info
KAIROS PHARMA LTD
2355 Westwood Blvd. #139
Los Angeles CALIFORNIA US
Employees: 0
Company Website: https://kairospharma.com
Phone: 18184045541
KAIROS PHARMA LTD / KAPA FAQ
What is the stock price of KAIROS PHARMA LTD today?
The current stock price of KAPA is 1.33 USD. The price increased by 0.76% in the last trading session.
What is the ticker symbol for KAIROS PHARMA LTD stock?
The exchange symbol of KAIROS PHARMA LTD is KAPA and it is listed on the NYSE Arca exchange.
On which exchange is KAPA stock listed?
KAPA stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for KAIROS PHARMA LTD stock?
7 analysts have analysed KAPA and the average price target is 9.18 USD. This implies a price increase of 590.23% is expected in the next year compared to the current price of 1.33. Check the KAIROS PHARMA LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is KAIROS PHARMA LTD worth?
KAIROS PHARMA LTD (KAPA) has a market capitalization of 18.22M USD. This makes KAPA a Nano Cap stock.
How many employees does KAIROS PHARMA LTD have?
KAIROS PHARMA LTD (KAPA) currently has 0 employees.
What are the support and resistance levels for KAIROS PHARMA LTD (KAPA) stock?
KAIROS PHARMA LTD (KAPA) has a support level at 1.32 and a resistance level at 1.37. Check the full technical report for a detailed analysis of KAPA support and resistance levels.
Should I buy KAIROS PHARMA LTD (KAPA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KAPA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KAPA, evaluating the profitability, health, valuation and growth aspects
- KAIROS PHARMA LTD (KAPA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KAIROS PHARMA LTD (KAPA) Sales and EPS estimates to see what analysts future expectations are.
- KAIROS PHARMA LTD (KAPA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KAIROS PHARMA LTD (KAPA) Insider and Institutional Ownership to learn about the owners and their transactions.
- KAIROS PHARMA LTD (KAPA) Stock Chart to make your own analysis
- KAIROS PHARMA LTD (KAPA) Latest news and press-releases to stay up to date.
Does KAIROS PHARMA LTD (KAPA) stock pay dividends?
KAPA does not pay a dividend.
What is the Price/Earnings (PE) ratio of KAIROS PHARMA LTD (KAPA)?
KAIROS PHARMA LTD (KAPA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.23).
What is the Short Interest ratio of KAIROS PHARMA LTD (KAPA) stock?
The outstanding short interest for KAIROS PHARMA LTD (KAPA) is 1.86% of its float. Check the ownership tab for more information on the KAPA short interest.
KAPA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to KAPA.
KAPA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to KAPA. The financial health of KAPA is average, but there are quite some concerns on its profitability.
KAPA Financial Highlights
Over the last trailing twelve months KAPA reported a non-GAAP Earnings per Share(EPS) of -0.23. The EPS decreased by -72.58% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.78% | ||
| ROE | -82.26% | ||
| Debt/Equity | 0.04 |
KAPA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to KAPA. The Buy consensus is the average rating of analysts ratings from 7 analysts.